Incretin Microdosing for Cardiometabolic Health in People With HIV
Status:
NOT_YET_RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
The objectives of this study are as follows:
Primary Objective
* To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy.
Secondary Objectives
* To evaluate the tolerability of semaglutide microdosing in adults with HIV.
* To evaluate changes in weight, waist circumference (WC) and body mass index (BMI) over 12 weeks (W) of semaglutide weight loss induction and 48 W of semaglutide microdosing therapy.
Phase:
PHASE2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborators:
Massachusetts General Hospital (MGH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) University of Colorado Denver - Anschutz Medical Campus (UCD-AMC)